Urology news for Saturday, October 17, 2026

Top 5 in urology

Phase 2a trial opens testing two dosing regimens of 177Lu-TLX250 in advanced clear cell RCC Trial opening · ClinicalTrials.gov · 2026-10-13
A multicenter phase 2a study (planned enrollment 40) will evaluate two dosing regimens of the CAIX-targeted radioligand therapy 177Lu-TLX250 in relapsed or recurrent clear cell renal cell carcinoma, aiming to determine a recommended phase 3 dose.
Why it matters: CAIX-targeted radioligand therapy represents an emerging treatment approach for clear cell RCC, a tumor type with few radiopharmaceutical options to date.
More Kidney cancer news
Delphi study defines 15 core entrustable professional activities for urology residency graduates Study · Urology · 2026-10-16
A national Delphi panel of academic urology educators distilled 242 candidate activities into 15 core EPAs that urology residents should perform independently by graduation, covering evaluation, medical management, and a narrower set of procedures.
Why it matters: Provides a competency-based framework that may inform future resident assessment and milestone evaluation in urology training programs.
AAP updates recommendations on management of UTI in children under age 5 Guideline · Renal & Urology News · 2026-10-16
The American Academy of Pediatrics has issued updated guidance on diagnosis and management of urinary tract infection in children under 5 years old.
Why it matters: Pediatric UTI guidance affects urology referral thresholds and imaging decisions for febrile young children.
More Pediatric urology news
Meta-analysis: PAMORAs linked to faster bowel recovery after radical cystectomy Meta-analysis · Transl Androl Urol · 2026-10-14
A systematic review and meta-analysis found that adding peripherally acting mu-opioid receptor antagonists (alvimopan, naloxegol, methylnaltrexone) to enhanced recovery pathways after radical cystectomy was associated with shortened time to first flatus and improved postoperative GI recovery versus enhanced recovery alone, though certainty of evidence varied and data specific to cystectomy remain limited and…
Why it matters: Suggests PAMORAs may help reduce postoperative ileus after cystectomy, but evidence quality is variable and more robust data are needed before routine incorporation into enhanced recovery protocols.
More Reconstruction and trauma news
FDA expands Anktiva approval to papillary-only BCG-unresponsive bladder cancer FDA approval · BioPharm International · 2026-10-15
FDA broadened the approval of nadofaragene/Anktiva (N-803) to include patients with papillary-only BCG-unresponsive non-muscle invasive bladder cancer, expanding its prior approval for CIS.
Why it matters: Gives clinicians an added intravesical option for BCG-unresponsive papillary disease, an area with limited bladder-sparing alternatives.
More Bladder cancer news

Prostate cancer news

Phase 3 trial launches comparing BNT324 to docetaxel in mCRPC Trial opening · NCI · 2026-10-16
A newly registered phase 3 trial will compare the antibody-drug conjugate BNT324 against docetaxel chemotherapy in metastatic castration-resistant prostate cancer. No efficacy or safety results are available yet.
Why it matters: A new ADC could offer an alternative to chemotherapy in mCRPC if the trial is positive.
Review: AI-based GP4 volume quantification not yet ready to refine active surveillance criteria Review · Eur Urol Focus · 2026-10-17
This review discusses how Gleason pattern 4 volume predicts outcomes in intermediate-risk prostate cancer but measurement is inconsistent; AI-based digital pathology tools show promise but remain insufficiently validated for clinical decisions.
Why it matters: Clinicians should be aware that AI-based GP4 quantification tools are investigational and not yet validated for guiding active surveillance eligibility.
Study finds wide variation in PSA referral thresholds across NHS trusts in England Study · BJU Int · 2026-10-17
This study examines variability in the PSA level thresholds used by NHS trusts across England to trigger referral for suspected prostate cancer, highlighting inconsistency in early detection pathways.
Why it matters: Inconsistent referral thresholds could contribute to inequitable access to timely prostate cancer diagnosis.
Higher baseline GDF15 linked to shorter survival in abiraterone-treated mCRPC in small cohort Retrospective · Clin Genitourin Cancer · 2026-10-17
In a retrospective analysis of 28 mCRPC patients on abiraterone, higher baseline serum GDF15 was independently associated with shorter overall survival (median 12 vs 42 months by median split) after adjustment for PSA50 response and visceral metastases.
Why it matters: Raises GDF15 as a candidate prognostic biomarker in mCRPC, though validation in larger prospective cohorts is needed before clinical use.
Randomized phase 2: talazoparib-enzalutamide met PSA goal but showed no clear benefit over enzalutamide alone RCT · Nat Med · 2026-10-16
In 54 men with high-volume mHNPC unselected for HRR mutations, talazoparib plus enzalutamide met its prespecified single-arm PSA response threshold (73% vs prespecified goal, P<0.001). The exploratory comparison to enzalutamide alone (64.7%) was not significant (P=0.54). Combination therapy caused more grade 3+ toxicity (68% vs 35%) including two fatal myeloid neoplasms.
Why it matters: Adding PARP inhibition to ARPI therapy in biomarker-unselected hormone-naive patients met its primary endpoint but showed no clear efficacy edge over enzalutamide alone in exploratory comparison, with added toxicity.
Meta-analysis: metformin added to ADT improves metabolic markers but not survival, per STAMPEDE-inclusive pooled data Meta-analysis · Prostate Cancer Prostatic Dis · 2026-10-16
Pooling six RCTs (2,415 patients, 78% from STAMPEDE), metformin plus ADT modestly reduced waist circumference, HbA1c, and fasting glucose at 12 months, while STAMPEDE itself showed no overall survival benefit (HR 0.91, p=0.15).
Why it matters: Clarifies that metformin may help offset ADT-associated metabolic syndrome but should not be used with an expectation of oncologic benefit.
Meta-analysis finds lower detected prostate cancer incidence in transgender women on hormone therapy Meta-analysis · Eur Urol Oncol · 2026-10-16
Pooled analysis of 54,342 transgender women on gender-affirming hormone therapy found a standardized incidence ratio of 0.224 versus cisgender men, but grade/stage data came from fewer than 40 cases with no matched comparison group.
Why it matters: Suggests GAHT may lower detectable prostate cancer risk, but evidence certainty is very low and should not change individualized screening discussions.
Focal salvage HDR brachytherapy shows low acute toxicity in phase I/II trial for radiorecurrent prostate cancer Phase 1-2 · J Clin Oncol · 2026-10-15
In the 62-patient F-SHARP phase I/II trial of dose-escalated focal salvage HDR brachytherapy after prior radiotherapy, no acute grade 3 toxicity occurred (2 patients had late grade 3 toxicity) and 3-year biochemical PFS was 62.7%. Among 31 patients with genomic classifier data, all 4 with scores above 0.85 experienced recurrence, suggesting a possible biomarker for risk stratification.
Why it matters: Supports focal salvage HDR brachytherapy as a low-acute-toxicity option for intraprostatic radiorecurrence; a small genomic classifier subset hints at a biomarker for treatment intensification, pending larger validation.
ARASENS substudy: darolutamide plus docetaxel shows no clinically relevant PK drug interaction Phase 3 RCT · Clin Genitourin Cancer · 2026-10-15
In this secondary dosing/safety/PK analysis of the phase 3 ARASENS trial, 87.6% of darolutamide patients and 85.5% of placebo patients completed 6 docetaxel cycles. Docetaxel plasma concentrations were similar with and without darolutamide, and darolutamide exposure was only 10% lower with docetaxel, neither considered clinically relevant.
Why it matters: Supports co-administering darolutamide with docetaxel and ADT in mHSPC without dose adjustment, based on a secondary PK/safety analysis of ARASENS.
Genomic test identifies candidates for ADT among intermediate-risk prostate cancer patients Study · Renal & Urology News · 2026-10-14
A study reports that a genomic classifier can help identify intermediate-risk prostate cancer patients who are likely to benefit from androgen deprivation therapy.
Why it matters: Could help refine ADT selection in intermediate-risk disease, an area of ongoing clinical uncertainty.

Bladder cancer news

Review outlines emerging combination strategies for BCG-unresponsive NMIBC beyond cystectomy Review · Nat Rev Urol · 2026-10-17
This review summarizes biological rationale and ongoing clinical strategies combining intravesical chemotherapy, BCG, immunotherapy, gene therapy and radiotherapy as bladder-preserving alternatives to cystectomy in BCG-unresponsive NMIBC.
Why it matters: Provides a framework for understanding the growing landscape of bladder-sparing combination therapies competing with cystectomy in BCG-unresponsive disease.
BOND-003 cohort C: cretostimogene shows cystectomy-free survival in BCG-unresponsive NMIBC with CIS Phase 1-2 · UroToday · 2026-10-16
A conference presentation reported cystectomy-free survival results for intravesical cretostimogene grenadenorepvec in patients with high-risk BCG-unresponsive NMIBC with carcinoma in situ, from the phase 3 BOND-003 trial cohort C.
Why it matters: Adds to the evidence base for an investigational oncolytic virus therapy as a bladder-sparing option in BCG-unresponsive CIS, from a single-arm phase 3 cohort.
BOND-003 Cohort P: single-arm study of cretostimogene in papillary-only BCG-unresponsive NMIBC Phase 1-2 · UroToday · 2026-10-16
UroToday previewed an AUA 2026 presentation titled Topline Results from BOND-003 Cohort P, a multinational single-arm study of intravesical cretostimogene grenadenorepvec in high-risk, papillary-only, BCG-unresponsive NMIBC. The source provides only the abstract title; no outcome data are reported here.
Why it matters: Adds pipeline context in the BCG-unresponsive papillary-only NMIBC space, but no efficacy or safety data are available from this source yet.
CORE-008 cohort A: Phase 2 PK/PD data on intravesical cretostimogene in BCG-naive high-risk NMIBC Phase 1-2 · UroToday · 2026-10-16
A Phase 2 study (CORE-008 cohort A) presented clinical and pharmacokinetic/pharmacodynamic insights on intravesical cretostimogene grenadenorepvec in patients with high-risk BCG-naive NMIBC, as announced for presentation at AUA 2026. Specific efficacy and safety data were not detailed in this source.
Why it matters: Early Phase 2 PK/PD data on an investigational intravesical gene therapy for BCG-naive high-risk NMIBC, to be presented at AUA 2026; details not yet available.
Meta-analysis assesses perioperative immunotherapy in cisplatin-eligible MIBC Meta-analysis · UroToday · 2026-10-14
A meta-analysis of randomized controlled trials evaluates perioperative immune-based treatment regimens in cisplatin-eligible muscle-invasive bladder cancer.
Why it matters: Synthesizes evidence across trials on an increasingly used treatment approach in MIBC.
Multi-institution cohort reports outcomes of gemcitabine/docetaxel for BCG-unresponsive NMIBC Prospective · Eur Urol Focus · 2026-10-14
In 63 patients with BCG-unresponsive NMIBC treated with sequential gemcitabine/docetaxel, 12-month high-grade recurrence-free survival was 68.1% and 12.7% underwent radical cystectomy; BCG-refractory disease had higher recurrence risk than early-relapsing disease.
Why it matters: Adds prospective multi-institutional data supporting intravesical gemcitabine/docetaxel as a bladder-sparing option for BCG-unresponsive NMIBC.
Australian practical guide outlines approach to muscle-invasive bladder cancer management Guideline · UroToday · 2026-10-13
A newly published Australian practical guide addresses management of muscle-invasive bladder cancer, per UroToday. Details on the guide's scope, authorship, and specific recommendations were not provided in the available source material.
Why it matters: May offer a regional practical reference for clinicians managing muscle-invasive bladder cancer, pending review of full content.
Phase 3 trial opens comparing T-bren antibody-drug conjugate to chemo in HER2+ metastatic urothelial cancer Trial opening · ClinicalTrials.gov · 2026-10-13
A phase 3 trial (planned enrollment 520) will compare trastuzumab brengitecan (T-bren) to standard platinum-based chemotherapy in HER2-expressing metastatic urothelial carcinoma progressing after anti-PD-(L)1 therapy.
Why it matters: Tests a novel HER2-targeted ADC as a post-immunotherapy option in a molecularly defined subgroup of metastatic urothelial cancer.
Review finds no NMIBC biomarker yet ready to replace standard risk tools Review · BJU Int · 2026-10-12
A narrative review of tissue, urinary and blood biomarkers for NMIBC prognosis found most evidence is retrospective and single-cohort, with inconsistent cutoffs and assays, and concluded none can currently replace guideline risk stratification or cystoscopy.
Why it matters: Reinforces that cystoscopic surveillance and established risk models remain standard despite growing biomarker research.

Kidney cancer news

Japanese database: no sharp 4-cm cutoff for PN selection; safety signal beyond 5 cm needs caution Retrospective · Clin Genitourin Cancer · 2026-10-17
Retrospective study of 36,015 T1 RCC patients across 941 Japanese hospitals found tumor size had a continuous, near-linear inverse association with odds of partial nephrectomy selection, with no distinct inflection at 4 cm. Among PN cases, adjusted odds of 30-day complication-free survival decreased with size up to about 5 cm, then appeared to plateau, a finding the authors say warrants cautious interpretation.
Why it matters: Suggests the 4-cm TNM threshold alone is insufficient for PN selection decisions; authors call for individualized assessment integrating tumor size, anatomical complexity, and surgical expertise rather than a fixed…
Delay beyond 3 months to partial nephrectomy linked to higher cancer mortality in younger patients Retrospective · Clin Genitourin Cancer · 2026-10-16
SEER analysis of 8,947 patients with 2-4 cm RCC found time to partial nephrectomy over 3 months was associated with higher cancer-specific mortality in patients aged 67 or younger (HR 1.62), with the strongest effect in those 55 or younger.
Why it matters: Supports prioritizing timely surgical scheduling for partial nephrectomy, particularly in younger renal mass patients.
Phase 2 trial: neoadjuvant radiation before IVC thrombectomy for RCC appears feasible Phase 1-2 · JAMA Oncol · 2026-10-16
Single-center prospective phase 2 nonrandomized trial gave neoadjuvant stereotactic ablative radiotherapy to IVC tumor thrombus before nephrectomy/thrombectomy in 23 patients with RCC; 22 completed surgery and 21 were evaluable for the primary 1-year recurrence-free survival endpoint, compared with a prespecified historical surgery-alone benchmark of 55.7%.
Why it matters: Offers a potential neoadjuvant strategy for a high-risk, technically challenging RCC subgroup with IVC tumor thrombus lacking established local therapies, pending larger confirmatory studies.
English NHS timely treatment rates for kidney cancer surgery fell sharply 2019-2023 Retrospective · BJU Int · 2026-10-12
In a population-based study of over 17,000 RCC patients, timely treatment (surgery within 31 days of decision) fell from 83.7% to 64.8% in high-risk and from 71.3% to 47.6% in low-risk RCC between 2019 and 2023, while prolonged delays (>62 days) more than doubled.
Why it matters: Highlights a system-wide erosion in surgical wait-time performance for kidney cancer with worsening prognostic implications once delay thresholds are breached.

Upper tract urothelial carcinoma news

FDG-PET/CT upstages 22% of high-risk UTUC cases beyond CT, changing treatment in 21% Retrospective · BJU Int · 2026-10-15
In a 203-patient cohort with suspected high-risk UTUC, adding FDG-PET/CT to CT led to clinically relevant stage migration in 22% of patients and altered treatment recommendations in 21%, with higher sensitivity for nodal metastases than CT (74% vs 33%).
Why it matters: FDG-PET/CT may refine staging and treatment selection in high-risk UTUC beyond conventional CT imaging.
Surgical delay of 43+ days to nephroureterectomy linked to worse overall survival in UTUC Retrospective · Clin Genitourin Cancer · 2026-10-07
In 435 patients with upper tract urothelial carcinoma, waiting 43 days or more from diagnosis to radical nephroureterectomy was associated with worse overall survival (HR 1.43) after inverse probability weighting, though cancer-specific and recurrence-free survival differences were not statistically significant.
Why it matters: Adds to evidence that timely surgery after UTUC diagnosis may matter, relevant to scheduling and referral pathways.
CT urography and cytology miss most recurrences during UTUC endoscopic surveillance Retrospective · BJU Int · 2026-09-30
In a two-center study of 133 patients undergoing kidney-sparing endoscopic treatment for UTUC, combined CT urography and cytology avoided about 69% of surveillance ureteroscopies but missed nearly 65% of recurrences, with cytology alone highly specific but poorly sensitive.
Why it matters: Suggests noninvasive imaging and cytology cannot safely replace ureteroscopy for UTUC surveillance despite reducing procedure burden.
Meta-analysis: ureteroscopic biopsy forceps yield ~85% diagnostic rate in UTUC, no device superior Meta-analysis · J Endourol · 2026-09-29
Pooling 19 studies and over 1,700 biopsies, flexible ureteroscopy forceps achieved 84.6% diagnostic yield and 78.8% grade concordance in upper tract urothelial carcinoma, with over half of apparently non-muscle-invasive tumors upstaged at nephroureterectomy, and no forceps design outperforming others.
Why it matters: Reinforces that ureteroscopic biopsy alone should not be relied upon to exclude muscle-invasive UTUC when planning kidney-sparing therapy.

Testicular cancer news

Post-chemo RPLND for seminoma: 84% 5-yr survival in viable seminoma cases, 27% relapsed overall Retrospective · J Urol · 2026-10-08
Retrospective multi-institutional study of 108 pure seminoma patients undergoing post-chemo RPLND for residual masses. Among those with viable seminoma on pathology, 5-year overall survival was 84%. Overall, 27% of patients relapsed and marker-negative progression independently predicted worse progression-free survival (p<0.001).
Why it matters: Retrospective data support EAU guidance on centralizing this technically demanding seminoma RPLND procedure, given its morbidity and relapse risk even with favorable survival in viable seminoma cases.
EAU panel recommends centralized care to improve testicular cancer outcomes Guideline · UroToday · 2026-09-25
A European Association of Urology guidelines panel report argues that treatment at higher-volume centers is associated with better outcomes for testicular cancer patients, supporting centralization of care.
Why it matters: Referral pathways and case volume may influence outcomes in a highly curable cancer where errors have long-term consequences.

Endourology and stone disease news

Multicenter registry: direct in-scope suction achieves 93% stone-free rate in ureteroscopy Prospective · Eur Urol Open Sci · 2026-10-15
In a 540-patient prospective registry across 16 centers, flexible ureteroscopy using a direct in-scope suction device achieved an overall 30-day stone-free rate of 93% (71% zero-residual-fragment), with low major complication rates.
Why it matters: Provides real-world prospective efficacy and safety data for an emerging suction-assisted ureteroscopy technology.
UK Biobank data show kidney stone incidence rises linearly with age, challenging prior assumptions Retrospective · J Endourol · 2026-10-15
Among nearly 495,000 UK Biobank participants followed 2010-2022, kidney stone incidence rose progressively with age (39.4 to 150.5 per 100,000 person-years from age 46 to 80), contrasting with the traditional view that risk peaks in middle age.
Why it matters: Suggests stone prevention and management should extend more deliberately into older age groups.
Systematic review: SGLT2 inhibitors linked to lower stone risk than GLP-1 or DPP-4 drugs in diabetics Review · Transl Androl Urol · 2026-10-14
An EAU Endourology systematic review of six observational studies found SGLT2 inhibitor use was associated with lower incident and recurrent urolithiasis risk than GLP-1 receptor agonists (HR 0.51-0.69) or DPP-4 inhibitors (HR 0.33-0.84) in patients with diabetes.
Why it matters: Suggests antidiabetic drug class choice may carry incidental stone-prevention implications relevant to counseling diabetic stone formers.

BPH and male LUTS news

Butterfly Prostatic Retraction Device receives EU MDR certification for BPH Intl regulatory · Urology Times · 2026-10-13
The Butterfly Prostatic Retraction Device has received EU MDR certification for treatment of BPH, according to Urology Times.
Why it matters: Adds another minimally invasive device option to the European BPH treatment landscape.
Systematic review and meta-analysis assesses safety and efficacy of Aquablation for BPH Meta-analysis · UroToday · 2026-10-12
A new systematic review and meta-analysis evaluated outcomes of Aquablation therapy for benign prostatic hyperplasia, but specific findings are not detailed in the available text.
Why it matters: Aquablation continues to accumulate comparative evidence as a BPH surgical option.
Meta-analysis compares aquablation to laser enucleation for BPH, includes first RCT Meta-analysis · UroToday · 2026-10-11
A systematic review and pairwise meta-analysis of head-to-head studies, including the first randomized trial, compares aquablation with laser enucleation of the prostate for BPH.
Why it matters: Helps urologists weigh two increasingly used minimally invasive BPH surgical options against each other.

Reconstruction and trauma news

Systematic review: incisional hernia after robotic prostatectomy varies widely, linked to extraction site Review · Eur Urol Open Sci · 2026-10-12
Across 16 mostly retrospective studies (56,661 patients), reported incisional hernia after minimally invasive radical prostatectomy ranged from 0.04% to 31%. Two comparative studies found lower rates with Pfannenstiel than periumbilical extraction, and three registry studies reported lower rates after open surgery than after MIRP. Evidence is limited by heterogeneous definitions and follow-up.
Why it matters: Observational data suggest specimen extraction site and surgical approach may influence incisional hernia risk after robotic prostatectomy, but evidence is heterogeneous and not yet definitive.
Augmentation cystoplasty shows durable urodynamic benefit over median 19 years in spinal cord injury Retrospective · BJU Int · 2026-10-10
In a retrospective cohort of 70 patients with spinal cord injury and refractory neurogenic bladder dysfunction, augmentation cystoplasty increased mean bladder capacity from 155 to 490 mL and reduced detrusor pressure from 72 to 19 cmH2O, with continence achieved in 67% over a mean 19-year follow-up; complications included urolithiasis (10%) and malignancy (4%).
Why it matters: Provides long-term reassurance on durability and complication rates for augmentation cystoplasty in a population with limited surgical alternatives.
Institutional experience improves 5-year outcomes for gender-affirming penile prosthesis Retrospective · J Sex Med · 2026-09-28
In a retrospective cohort of 473 patients undergoing first-time gender-affirming inflatable penile prosthesis insertion, cumulative institutional experience, single-cylinder implantation, and use of one device brand were linked to lower risk of subsequent surgery, with peak proficiency identified around case 311.
Why it matters: Highlights a long learning curve for gender-affirming IPP surgery, relevant for centers building or scaling these programs.
Novel laparoscopic technique described for refractory piriformis-related pelvic pain Retrospective · J Endourol · 2026-09-26
A retrospective series of 200 patients across multiple institutions describes a transgluteal laparoscopic piriformis muscle transection technique for chronic pelviperineal pain syndrome, reporting technical feasibility with low morbidity and short hospital stay.
Why it matters: Introduces a minimally invasive surgical option for a difficult-to-treat and underrecognized cause of chronic pelvic pain.

Men's health news

Phase 3 trial tests clomipramine plus sildenafil combo for premature ejaculation Phase 3 RCT · UroToday · 2026-10-12
A multicenter phase 3 randomized trial compared on-demand clomipramine/sildenafil combination therapy to either drug alone in men with premature ejaculation.
Why it matters: Combination on-demand regimens could offer an option for men who respond poorly to single-agent therapy.

Pediatric urology news

Higher chemotherapy dose and testicular radiation linked to abnormal pubertal hormone patterns in childhood cancer survivors Retrospective · JAMA Netw Open · 2026-10-10
In a cohort of 221 male childhood cancer survivors, cumulative alkylating chemotherapy dose and testicular radiotherapy above 1 Gy were associated with dose-dependent elevations in pubertal FSH levels, a marker of impaired gonadal function.
Why it matters: Supports using cumulative treatment exposure data to guide early fertility counseling discussions in childhood cancer survivors reaching puberty.
Temporary vesicostomy cuts early complications after pediatric bladder augmentation Retrospective · Neurourol Urodyn · 2026-10-01
In 168 children undergoing ileocystoplasty with catheterizable stoma, temporary incontinent vesicostomy was associated with markedly lower rates of anastomotic leakage, stoma obstruction, and febrile UTI (2.3% vs 28.6% overall complication rate), without affecting 24-month continence or bladder dynamics.
Why it matters: Offers a technical strategy to reduce early morbidity and emergency readmissions after a common pediatric reconstructive procedure.
Review proposes risk-stratified framework for observation versus treatment of pediatric varicocele Review · Nat Rev Urol · 2026-10-01
This narrative review synthesizes evidence on pediatric varicocele management, noting lack of consensus, and proposes a risk-stratified model using grade, testicular volume asymmetry, and semen/hormonal parameters to guide observation versus early intervention.
Why it matters: Offers a practical framework for a common but controversial pediatric urology decision where high-quality outcome data are limited.
New reference curves define expected residual hydronephrosis after pyeloplasty Retrospective · World J Urol · 2026-09-27
In 566 renal units after pyeloplasty, postoperative APD reference curves were built from units without recurrence. Renal pelvic APD above the 90th centile curve was linked to a much higher reoperation rate (11.7% vs 0.8%).
Why it matters: Offers an objective benchmark to decide which children with residual postoperative dilation need closer follow-up versus reassurance.
Insurance status and timing linked to orchiectomy odds after testicular torsion in NY state Retrospective · J Pediatr Urol · 2026-09-27
Among 4,159 children with testicular torsion in New York State over 15 years, 26% underwent orchiectomy; government or self-pay insurance and presentation timing were associated with higher orchiectomy odds, with effects varying by age group.
Why it matters: Points to potential access or systems-level disparities affecting testicle salvage rates that may warrant institutional review.

Technology and AI news

Urologists could not reliably distinguish AI-written from human-written study abstracts Study · World J Urol · 2026-10-17
In a study of 15 urology papers with human and AI-generated abstracts (Claude, GPT, Gemini) read blinded by 8 urologists, reviewers correctly identified AI-written abstracts only 49% of the time versus 62% for human abstracts, with accuracy varying by AI model.
Why it matters: Highlights that current AI models can produce abstracts indistinguishable from human writing, with implications for peer review and literature integrity.

More urology news

Randomized trial opens comparing ADC plus immunotherapy to chemo plus immunotherapy in unresectable high-risk NMIBC Trial opening · ClinicalTrials.gov · 2026-10-16
A new randomized phase 2 trial will compare an antibody-drug conjugate plus immunotherapy against immunotherapy plus chemotherapy in patients with extensive, transurethrally unresectable very-high-risk NMIBC. No results are available yet.
Why it matters: Addresses an unmet need for bladder-preserving options in patients who cannot undergo complete TURBT.
Phase 2 trial opens testing ivonescimab combinations in advanced clear cell RCC Trial opening · ClinicalTrials.gov · 2026-10-16
A new phase 2 trial will evaluate ivonescimab alone or combined with cadonilimab or ipilimumab in advanced clear cell renal cell carcinoma. No results are yet available.
Why it matters: Represents a new immunotherapy combination strategy under investigation for advanced RCC.
Phase 3 trial of deutenzalutamide plus ADT opens for high-risk biochemically recurrent prostate cancer Trial opening · ClinicalTrials.gov · 2026-10-15
A planned 1,044-patient randomized, double-blind, placebo-controlled phase 3 trial will test deutenzalutamide plus ADT versus placebo plus ADT in men with high-risk biochemical recurrence after definitive therapy for prostate cancer.
Why it matters: A new androgen receptor inhibitor is entering phase 3 testing in the biochemical recurrence setting, an area with evolving treatment intensification strategies.
AUA Census: fellowship-trained urologists rose from 40% to 46% over a decade, general urology fell Retrospective · Urology · 2026-10-06
Analysis of 2014-2024 AUA Census data shows fellowship-trained urologists increased from 40% to 46% while general urologists decreased from 63% to 54%, with subspecialists concentrated in academic and metropolitan settings.
Why it matters: Highlights a growing access gap as subspecialization trends toward academic, urban practice, with implications for rural and community urology coverage.

Loading today's edition…